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Endothelin receptor antagonists
Endothelin (ET-1) is a potent vasoconstrictor consisting of 21 amino acids. This peptide and
two other structurally and functionally related vasoconstricting peptides, termed endothelin-2
and endothelin-3, interact with two known G-protein coupled receptors ETA and ETB and
induce vasoconstricting effects. ETA, ETB, and more recently discovered ETC are tissue
specific and are displayed preferentially in varying proportions on different cell types. ETA is
found in vascular smooth muscle tissue and is mainly responsible for vasoconstriction of
smooth muscle cells, while ETB, which is found in nonvascular smooth muscle tissues, has
been implicated in the release of endothelial-derived relaxing factors. Elevated levels of
endothelin are found in patients suffering from a variety of diseases including hypertension,
pulmonary hypertension, and cerebral vasospasm, and evidence is accumulating that newer ET
antagonists may not only provide a novel therapy for the treatment of such diseases but also
help in understanding the precise physiological roles of endothelins.
In an effort to discover new ET antagonists, a small library of 15 peptoid compounds was
synthesised in solution (Peptoids as endothelin receptor antagonists, F. Dasgupta et. al.,
Bioorg. Med. Chem. Lett., 11, (2001), 555-557). Screening of these compounds revealed their
affinity for endothelin receptors in terms of their ability to competitively inhibit ET. One of the
most potent compounds discovered was (1) with an IC50 value of 660 nM against ETB and 13-
fold selectivity over ETA. This library has been successful in providing novel peptoids
possessing a range of ETA and ETB receptor affinities. Future work may be directed at
comparing biophore mapping of this series with the energy minimised 3-D model of other
active compounds from the literature which may aid in the design of further compounds with
improved activity.
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Dopamine D4 receptor partial agonists
Recent advances in molecular cloning techniques have led to the characterisation of a number
of dopamine receptor subtypes which can be divided into the D1-like and D2-like families.
Whereas the D1-like family comprises D1 and D5 subtypes, the D2-like family consists of D2,
D3 and D4 receptors. Due to the preferred expression of messenger RNA for dopamine
receptors in the frontal cortical and mesolimbic areas, considerable interest has been focused
on selective D4 antagonists. According to recent neuropathological and genetic studies
(Evidence that the dopamine D4 receptor is a susceptibility gene in attention deficient
hyperactivity disorder, S. L. Smalley et. al., Mol. Psychiatry, (1998), 3, 427-430), selective
dopamine D4 receptor agonists, partial agonists or antagonists, might be of interest for the
treatment of neuropsychiatric disorders including attention-deficient hyperactivity, mood
disorders and Parkinson's disease (Cyanoindole derivatives as highly selective dopamine D4
receptor partial agonists: solid-phase synthesis, binding assays, and functional experiments, P.
Gmeiner et. al., J. Med. Chem., 43, (2000), 4563-4569). A small library of 13 compounds was
synthesised on solid phase. One of the most potent compounds isolated was (2) which
possessed a Ki value for human D4 affinity of 0.52 nM, and 25000-, 6000-, 550-, and 3300-
fold selectivity over the bovine D1, human D2long, human D2short, and human D3 receptors
respectively. This library has been successful in generating highly potent and selective D4
receptor binding compounds. In the future, selective D4 partial agonists could serve as
interesting tools for the treatment of neuropsychiatric disorders such as attention-deficient
hyperactivity.
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